190 related articles for article (PubMed ID: 17073711)
21. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
Weiskopf RB
Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
[TBL] [Abstract][Full Text] [Related]
22. Recombinant factor VIIa: a general hemostatic agent? Not yet.
Levi M
J Thromb Haemost; 2004 Oct; 2(10):1695-7. PubMed ID: 15456476
[No Abstract] [Full Text] [Related]
23. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development.
Jurlander B; Thim L; Klausen NK; Persson E; Kjalke M; Rexen P; Jørgensen TB; Østergaard PB; Erhardtsen E; Bjørn SE
Semin Thromb Hemost; 2001 Aug; 27(4):373-84. PubMed ID: 11547359
[TBL] [Abstract][Full Text] [Related]
24. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis.
Meijer K; Hendriks HG; De Wolf JT; Klompmaker IJ; Lisman T; Hagenaars AA; Slooff MJ; Porte RJ; van der Meer J
Blood Coagul Fibrinolysis; 2003 Feb; 14(2):169-74. PubMed ID: 12632027
[TBL] [Abstract][Full Text] [Related]
25. Recombinant activated factor VII in clinical practice: a 2014 update.
Franchini M; Crestani S; Frattini F; Sissa C; Bonfanti C
J Thromb Thrombolysis; 2015 Feb; 39(2):235-40. PubMed ID: 25015059
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic treatment of a small child with severe factor VII deficiency using repeat dosing from a single vial of recombinant activated factor VII.
Michaels LA; Philipp CS; Eisele J; Pappas H; Saidi P
Pediatr Blood Cancer; 2007 Oct; 49(5):736-9. PubMed ID: 16317734
[TBL] [Abstract][Full Text] [Related]
27. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
Mariani G; Konkle BA; Ingerslev J
Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
[TBL] [Abstract][Full Text] [Related]
28. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
Tcheng WY; Donkin J; Konzal S; Wong WY
Haemophilia; 2004 May; 10(3):295-8. PubMed ID: 15086331
[TBL] [Abstract][Full Text] [Related]
29. Recombinant factor VIIa treatment for asymptomatic factor VII deficient patients going through major surgery.
Livnat T; Shenkman B; Spectre G; Tamarin I; Dardik R; Israeli A; Rivkind A; Shabtai M; Marinowitz U; Salomon O
Blood Coagul Fibrinolysis; 2012 Jul; 23(5):379-87. PubMed ID: 22527290
[TBL] [Abstract][Full Text] [Related]
30. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
[TBL] [Abstract][Full Text] [Related]
31. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
32. Factor VII deficiency.
Perry DJ
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S47-54. PubMed ID: 14567537
[TBL] [Abstract][Full Text] [Related]
33. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review.
Mathew P
Thromb Haemost; 2004 Oct; 92(4):738-46. PubMed ID: 15467904
[TBL] [Abstract][Full Text] [Related]
34. Factor VII deficiency and its treatment in delivery with recombinant factor VII.
Pehlivanov B; Milchev N; Kroumov G
Eur J Obstet Gynecol Reprod Biol; 2004 Oct; 116(2):237-8. PubMed ID: 15358473
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of action of factor VIIa in the treatment of coagulopathies.
Hedner U
Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():77-85. PubMed ID: 16673269
[TBL] [Abstract][Full Text] [Related]
36. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
Campbell RA; Fischer TH; Wolberg AS
Br J Haematol; 2007 Jul; 138(1):82-93. PubMed ID: 17555451
[TBL] [Abstract][Full Text] [Related]
37. The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders.
van't Veer C; Mann KG
Semin Thromb Hemost; 2000; 26(4):367-72. PubMed ID: 11092210
[TBL] [Abstract][Full Text] [Related]
38. Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
Goodnough LT
Semin Hematol; 2004 Jan; 41(1 Suppl 1):25-9. PubMed ID: 14872417
[TBL] [Abstract][Full Text] [Related]
39. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect.
Morfini M; Batorova A; Mariani G; Auerswald G; Bernardi F; Di Minno G; Dolce A; Fede C; Giansily-Blaizot M; Ingerslev J; Martinowitz U; Napolitano M; Pinotti M; Schved JF;
Thromb Haemost; 2014 Aug; 112(2):424-5. PubMed ID: 24763923
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
